(Q28264146)

English

Exploiting tumour hypoxia in cancer treatment

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

0 references

1 reference

Europe PubMed Central

Exploiting tumour hypoxia in cancer treatment (English)

0 references

0 references

author name string

J Martin Brown

1

0 references

William R Wilson

2

0 references

language of work or name

0 references

publication date

June 2004

0 references

Nature Reviews Cancer

0 references

4

0 references

6

0 references

437-47

0 references

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

1 reference

https://api.crossref.org/works/10.1038/NRC1367

21 April 2017

Targeting HIF-1 for cancer therapy

1 reference

https://api.crossref.org/works/10.1038/NRC1367

21 April 2017

Combination bacteriolytic therapy for the treatment of experimental tumors

1 reference

https://api.crossref.org/works/10.1038/NRC1367

21 April 2017

Hypoxia--a key regulatory factor in tumour growth

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

21 April 2017

Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

21 April 2017

The histological structure of some human lung cancers and the possible implications for radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Clinical trials of radiosensitizers: What should we expect?

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Conventional cancer therapy: promise broken or promise delayed?

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Mutagenesis induced by the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Microenvironment-induced cancer metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

The hypoxic tumour microenvironment and metastatic progression

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

A mass spectrometry study of tirapazamine and its metabolites. insights into the mechanism of metabolic transformations and the characterization of reaction intermediates

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors.

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Tumour cytochrome P450 and drug activation

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

AQ4N: a new approach to hypoxia-activated cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Hypoxia-Specific Cytotoxins in Cancer Therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs).

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Recent advances in bioreductive drug targeting

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Bioreductive therapies: an overview of drugs and their mechanisms of action

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

The experimental development of bioreductive drugs and their role in cancer therapy.

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: implications for extravascular transport and activity in tumors

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Oxygen dependence of the cytotoxicity and metabolic activation of 4-alkylamino-5-nitroquinoline bioreductive drugs

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Exploiting tumor hypoxia through bioreductive release of diffusible cytotoxins: the cobalt(III)-nitrogen mustard complex SN 24771

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Identification of a hypoxic population of bone marrow cells

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation.

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Synthesis and evaluation of nitroheterocyclic phosphoramidates as hypoxia-selective alkylating agents.

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Hypoxia-selective antitumor agents. 16. Nitroarylmethyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Modifying rates of reductive elimination of leaving groups from indolequinone prodrugs: a key factor in controlling hypoxia-selective drug release

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Pathways of reductive fragmentation of heterocyclic nitroarylmethyl quaternary ammonium prodrugs of mechlorethamine

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Optimization of the auxiliary ligand shell of Cobalt(III)(8-hydroxyquinoline) complexes as model hypoxia-selective radiation-activated prodrugs.

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

A novel class of antitumor prodrug, 1-(2'-oxopropyl)-5-fluorouracil (OFU001), that releases 5-fluorouracil upon hypoxic irradiation

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

The Expression and Distribution of the Hypoxia-Inducible Factors HIF-1α and HIF-2α in Normal Human Tissues, Cancers, and Tumor-Associated Macrophages

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Hypoxia-mediated tumour targeting

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N.

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

The macrophage - a novel system to deliver gene therapy to pathological hypoxia

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Expression of HIF-1alpha by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

HIF-1 as a target for drug development

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Suppression of tumor growth through disruption of hypoxia-inducible transcription

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1.

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

The liquefaction (oncolysis) of malignant gliomas by a non pathogenic Clostridium

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954.

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Clostridia in cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT.

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

2,4-dinitro-5-ethyleneiminobenzamide (CB 1954): a potent and selective inhibitor of the growth of the Walker carcinoma 256.

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

The nitroreductase enzyme in walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-YL)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2)

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--I. Purification and properties of a nitroreductase enzyme from Escherichia coli--a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT).

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Radiosensitizing and Cytotoxicity Studies with CB 1954 (2,4-Dinitro-5-Aziridinylbenzamide)

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Measurement of Human Tumour Oxygenation Status by a Polarographic Needle Electrode: An analysis of inter- and intratumour heterogeneity

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Oxygenation of squamous cell carcinoma of the head and neck: comparison of primary tumors, neck node metastases, and normal tissue

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Hypoxia in breast cancer: pathogenesis, characterization and biological/therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Pancreatic tumors show high levels of hypoxia

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Oxygen tension in human tumours measured with polarographic needle electrodes and its relationship to vascular density, necrosis and hypoxia

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Oxygenation predicts radiation response and survival in patients with cervix cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Hypoxia in human prostate carcinoma: an Eppendorf PO2 study

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1038%2FNRC1367

31 March 2020

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28264146&oldid=2175166104"